Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
Genfit (NASDAQ:GNFT) saw its stock decline 9% following the company’s announcement to discontinue its VS-01 therapy for Acute-on-Chronic Liver Failure (ACLF). The decision came after a safety incident ...
Genfit SA is discontinuing its VS-01 program in acute-on-chronic liver failure (ACLF), and has decided to reprioritize development of VS-01 for urea cycle disorder.
Genfit predicted that axing the development of VS-01 in acute-on-chronic liver failure will substantially reduce its spending. (iStock / Getty Images Plus) Genfit has stopped development of VS-01 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results